RxDoctor Payments Data

Toral Patel, MD

Internal Medicine · Chicago, ILNPI 1902008006

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $78,137 of the $125,029 with a category attached, or 62.5%. 20 manufacturers reported payments, led by Viiv Healthcare Company at 41.3% of the total. Reporting peaked in 2019 at $60,292 and has fallen 98.5% since, to $917 in 2025. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$125,029in general payments, 2019–2025

Across 546 payments — averaging $228.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$52K
  • Melinta Therapeutics, LLC$29K
  • Gilead$24K
  • Merck$13K
  • Theratechnologies Inc.$3K
  • GSK$1K
  • plus $3K from 14 others

What the payments were for

  • Consulting fees$20,47016%
  • Speaking & faculty fees$78,13762%
  • Travel & lodging$13,22211%
  • Food & beverage$13,09110%
  • Education$990%
  • Gifts$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$125,029 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$102,045
Medicare patients
121
Services billed
861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TivicayDolutegravir Sodium44$147,389
BiktarvyBictegrav/Emtricit/Tenofov Ala27$115,933
DovatoDolutegravir Sodium/Lamivudine31$114,363
JulucaDolutegravir/Rilpivirine28$108,100
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf20$98,506
PrezcobixDarunavir/Cobicistat39$98,155
DescovyEmtricitabine/Tenofov Alafenam31$84,381
Etravirine11$11,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Dovato, Juluca$51,689$369,851103 claims
GileadBiktarvy, Descovy$24,001$200,31358 claims
Janssen Products, LPSymtuza$263$98,50620 claims
Johnson & JohnsonPrezcobix$700$98,15539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →